%0 Journal Article
%T Treatment of bone loss in patients with chronic liver disease awaiting liver transplantation
%A Daniel Kaemmerer
%A Benjamin Schmidt
%A Gabriele Lehmann
%A Gunter Wolf
%A Utz Settmacher
%A Merten Hommann
%J Transplantation Research
%D 2012
%I BioMed Central
%R 10.1186/2047-1440-1-7
%X In a retrospective study, we investigated the effect of pre-treatment with oral monthly ibandronate (150 mg), vitamin D3 (800 IU/day) and calcium (1 g/day) for osteopenia and osteoporosis caused by end-stage liver disease in patients before and after liver transplantation (LT).The bone mineral density (BMD) of the lumbar spine (LS) and the femoral neck was measured prospectively pre- and post-LT in 31 patients with existing pre-transplant osteopenia. Patients had osteopenia of the LS prior to LT (T-score £¿1.8£¿¡À£¿1.5) so that the treatment medication was initiated immediately after the diagnosis.The study group showed a permanently increased BMD with significant differences (g/cm2) from baseline up to 12 months post LT at the lumbar spine (LS: pre-LT 0.80£¿¡À£¿0.11 g/cm2, three months: 0.90£¿¡À£¿0.08 (P£¿<0.005); six months: 0.95£¿¡À£¿0.11 (P£¿<£¿0.008); 12 months: 1.00£¿¡À£¿0.09 -0.85 (P£¿<0.012).The combined pre- and post-operative treatment with oral ibandronate had significantly improved bone mineral density of the lumbar spine at 3, 6 and 12 months post LT. The immediate post-operative bone loss after LT can be significantly avoided by pre-treatment of liver transplant candidates affected by osteopenia.
%K Bone mineral density
%K Osteoporosis
%K Ibandronate
%K Liver transplantation
%K Chronic liver disease
%U http://www.transplantationresearch.com/content/1/1/7/abstract